Long-Term

Long-Term Mortality Associated With Use of Carvedilol Versus Metoprolol in Heart Failure Patients With and Without Type 2 Diabetes: A Danish Nationwid...

Background Carvedilol may have favorable glycemic properties compared with metoprolol, but it is unknown if carvedilol has mortality benefit over metoprolol in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF). Methods and Results Using Danish nationwide databases between 2010 and 2018, we followed patients with new-onset HFrEF treated with either carvedilol or metoprolol for all-cause mortality until the end of 2018. Follow-up started 120 days after initial HFrEF diagnosis to allow initiation of guideline-directed medical therapy. There were 39 260 p...

Elevated Stress Hormones Linked to Higher Risk of Hypertension, Cardiovascular Events

Adults with normal blood pressure and high levels of stress hormones were more likely to develop hyp...

Safety and efficacy of BNT162b2 mRNA COVID-19 vaccine through 6 months

Through 6 months of follow-up and despite a gradual decline in vaccine efficacy, the BNT162b2 (Pfize...


Suggested videos

Search:
Date
Filters:
Should Cur
16:32

Should Cure Be A Reasonable Goal in aRCC?

Presenter: David F. McDermott
Oncology
ESMO 2021
Is Unresec
6:32

Is Unresectable Malignant Pleural Mesothelioma a New Frontier for I-O?

Presenter: Alessandra Curioni-Fontecedro
Oncology
ESMO 2021
The Keynot
7:05

The Keynote 716 trial

Presenter: Jason J. Luke
Oncology
ESMO 2021
Navigating
5:56

Navigating a New Era in HER2+ Metastatic Breast Cancer: Focus on HER2CLIMB

Presenter: Judy King
Oncology
ESMO 2021
Metastases
7:04

Metastases-free survival results from STAMPEDE trial

Presenter: Gerhardt Attard
Oncology
ESMO 2021
Navigating
5:19

Navigating a New Era in HER2+ Metastatic Breast Cancer: Focus on HER2CLIMB

Presenter: Wolfgang Janni
Oncology
ESMO 2021
Highlights
10:39

Highlights of the ESMO 2021 Congress

Presenter: Solange Peters
Oncology
ESMO 2021
SSaSS: Sal
3:42

SSaSS: Salt Substitute and Stroke Study into the effect of salt substitutes on cardiovascular events and death

Presenter: Bruce Neal
Cardiology
ESC 2021
2021 ESC G
7:39

2021 ESC Guidelines - CVD Prevention

Presenter: Frank Visseren
Cardiology
ESC 2021
The digita
11:38

The digital age: The future of respiratory medicine

Presenter: Henry Chrystyn
Respiratory
ERS 2021
Antithromb
5:30

Antithrombin Deficiency Registry, an Update

Presenter: Zsuzsanna Bereczky
Hematology
ISTH 2021
Pulmonary
7:05

Pulmonary hypertension and interstitial pulmonary fibrosis

Presenter: Vincent Cottin
Respiratory
ERS 2021
ERS/EAACI
8:50

ERS/EAACI statement on adherence to international adult asthma guidelines

Presenter: Alexander Mathioudakis
Respiratory
ERS 2021
The curren
16:03

The current management of Angina

Presenter: Mario Marzilli
Cardiology
ESC 2021
LOOP Study
9:21

LOOP Study: screening for AF with an implantable loop recorder to prevent stroke

Presenter: Jesper Hastrup Svendsen
Cardiology
ESC 2021
TOMAHAWK:
3:45

TOMAHAWK: immediate angiography after out-of-hospital cardiac arrest

Presenter: Steffen Desch
Cardiology
ESC 2021
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients.

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology